It’s a bit of a weak comparison to contrast these completed deals with Faron’s potential partnerships or acquisitions, because neither of these completed deals is affected by the end point uncertainty (OS versus CR) that has frozen Faron’s partnering efforts. Your comments give me a bit of a “why not Faron, when these others…” vibe. The most dire prognostications have certainly already left the discussion.
At least I understand that a potential partner wants certainty on that end point issue first. And, at the latest after f2b (if the results are good), things will start happening. It would be crazy for BP (big pharma) to let the research continue to f3 if the prospects are favorable. Even now, a very early-stage asset was acquired.